Skip menus, go to main page content

To Our Shareholders
and Investors

Top
To Our Shareholders and Investors

IR News

February 10, 2026

R & D

RGX-121: REGENXBIO received Complete Response Letter from the U.S. FDA for Biologics License Application for mucopolysaccharidosis type II
February 09, 2026

Corporate

Notice Regarding Executive Personnel Changes
February 09, 2026

Management & Finance

Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2025
January 29, 2026

R & D

Regulatory Update on RGX-111 and RGX-121

Upcoming Events

February 09, 2026
IR Meeting (Q3/FY2025)
February 09, 2026
FY2025 3rd Qtr Results Announcement
November 14, 2025
IR Meeting(Q2/FY2025)
November 14, 2025
FY2025 2nd Qtr results announcement
August 07, 2025
Conference Call(Q1/FY2025)

Financial/Capital Strategy

Management Policy and Plan

Business/Financial Information

IR Library

Sustainability Management

Stock and Shareholder Information

To Our Individual Investors

IR e-mail

Subscribe (only 1 minute required) to receive the latest news by e-mail.

Most Viewed Pages

January 1-31, 2026

All Japanese Listed Companies' Website Ranking

Gomez
IR Site Ranking Silver 2025

Daiwa Investor Relations Co.Ltd. 2025 Internet IR Award

Related Link

Nippon Shinyaku’s DNA

Research & Development

Top
To Our Shareholders and Investors